# Organic & Biomolecular **Chemistry**

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

*Accepted Manuscripts* are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](http://www.rsc.org/Publishing/Journals/guidelines/AuthorGuidelines/JournalPolicy/accepted_manuscripts.asp).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](http://www.rsc.org/help/termsconditions.asp) and the Ethical quidelines still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.



www.rsc.org/obc

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

### **Oxidative cross-coupling of pyridine** *N***-oxides and ethers between**   $C(sp^2)$ – $H/C(sp^3)$ – $H$  bond under transition-metal-free conditions

**Wei Sun,***<sup>a</sup>*  **Zuguang Xie,***<sup>a</sup>*  **Jie Liu,\****<sup>a</sup>*  **and Lei Wang\****a,b*

*Received (in XXX, XXX) Xth XXXXXXXXX 20XX, Accepted Xth XXXXXXXXX 20XX*  <sup>5</sup>**DOI: 10.1039/b000000x** 

**A novel and efficient method based on the cross-coupling reactions of pyridine** *N***-oxides with ethers between**  $C(sp^2)$ **– H/C(sp3 )–H bonds in the presence of TBHP was developed. The strategy provides an alternative approach to pyridine**  <sup>10</sup>**moiety under transition-metal-free conditions.** 

Pyridine moiety are ubiquitous in natural products, pharmaceuticals and synthetic building blocks.<sup>1</sup> However, most of the methods for their preparation require prefunctionalization due to the low reactivity and poor regioselectivity of pyridine ring, 15 so much efforts have been devoted to exploring the direct functionalization of *N*-activated pyridinium species, including neutral pyridinium ylides, cationic pyridinium salts, and especially pyridine *N*-oxides, which have emerged as promising alternatives for the activation and functionalization of the

- <sup>20</sup> pyridine rings.<sup>2</sup> A number of methods for the direct α-arylation,<sup>3</sup> alkylation,<sup>4</sup> alkenylation<sup>1a,2d,5</sup> of pyridine *N*-oxides, as well as introduction of halides<sup>6</sup> into their structures have been developed in the presence of palladium and copper catalysts. General approaches for the synthesis of pyridine derivatives while
- 25 pyridine *N*-oxides as raw material is shown in Scheme 1. One of the methods as illustrated in Eq. 1 of Scheme 1, the electrophilic character of the 2-position can be enhanced with an activating agent (A−Y), allowing for nucleophilic addition under relatively mild conditions. Unfortunately, there are quite common side
- 30 reactions, including addition at the 4-position, and the direct reaction of activating agent with the nucleophile.<sup>7</sup> On the other hand, the scope of the direct cross-coupling partners has broadened into aryl halides, alkenes, arylboronic acid, and so on.<sup>2</sup> In this case, the use of a transition-metal catalyst is essential both 35 for C−H bond activation and functionlization to form C−C bond
- (Scheme 1, Eq. 2).



**Scheme 1** General methods for the formation of pyridine derivatives from pyridine *N*-oxides

It is well known that the conversion of C−H bonds directly into C−C bonds can provide more benefits in terms of environmental sustainability and potentially lead to more efficient synthesis.<sup>8</sup> Thus far, considerable development has been made in the area of oxidative C(sp)–H and C(sp<sup>2</sup>)–H cross-couplings for

45 the various C−C bonds forming reactions.<sup>9</sup> It is important to note that the oxidative couplings involving  $C(sp^3)$ –H bonds have been shown the signs of progress.<sup>10</sup> Based on the above achievements made in the area of *N*-activated pyridinium species and the conversion of C−H bonds into C−C bonds, development of a mild, 50 general and selective method for the preparation of 2-substitued pyridines through the direct C−H functionalization is highly desirable (Scheme 2), even the cross-coupling involved  $C(sp^3)$ -H bond is a challenging project in the absence of transition metal, and only one example of the reaction of pyridine *N*-oxide 55 derivatives with alkanes has been reported.<sup>1</sup>



**Scheme 2** The oxidative cross-coupling of pyridine *N*-oxides with C(sp3)−H bonds under metal-free conditions

In our continuing efforts on the C−H activation and 60 functionalization under the transition-metal-free conditions,<sup>12</sup> herein, we wish to disclose a direct C-2 alkylation of pyridine *N*oxides, through a dehydrogenative C−C cross-coupling reactions between 2-position C(sp2 )−H bond of pyridine *N*-oxides with αposition C(sp<sup>3</sup> )−H of ethers in the presence of *tert*-butyl 65 hydroperoxide (TBHP) under metal-free conditions (Scheme 3). The reaction generated the good yields of the corresponding products, which are very important class of heterocycles that have numerous applications for various biologically active compounds and organic functional materials.<sup>13</sup>



**Scheme 3** Dehydrogenative C−C cross-coupling reactions between pyridine *N*-oxides with ethers

This journal is © The Royal Society of Chemistry [year] *[journal]*, [year], **[vol]**, 00–00 | **1**

Paper

We focused our initial investigation on the optimization of conditions for the model reaction of pyridine *N*-oxides (**1a**) with tetrahydrofuran (THF, **2a**). When the model reaction was carried out in the presence of H<sub>2</sub>O<sub>2</sub>, 3-chloroperoxybenzoic acid (*m*-

- $5$  CPBA), di(*tert*-butyl) peroxide (DTBP) or  $K_2S_2O_8$  as oxidant, no desired cross-coupling product **3a** was observed (Table 1, entries 1−4). As *tert*-butyl hydroperoxide (TBHP, 70% aqueous) has been widely used as an efficient oxidant in the oxidative coupling reactions,<sup>11,12,14</sup> we tried TBHP (2.0 equiv, 70% aqueous) as
- 10 oxidant in the model reaction initially, but only 25% yield of **3a** was obtained (Table 1, entry 5). Cumyl hydroperoxide (CHP) was less effective, leading to 20% yield of **3a** (Table 1, entry 6). Further experiments showed that the product yield could be improved to 35% when the amount of TBHP was increased to
- 15 fourfold (Table 1, entry 7). Then, various bases were examined for the model reaction using TBHP (70% aqueous) as an oxidant. However, organic base such as DBU failed to promote the reaction (Table 1, entry 8). The product yields were enhanced slightly when other inorganic bases including  $Na<sub>2</sub>CO<sub>3</sub>, Cs<sub>2</sub>CO<sub>3</sub>, t$
- 20 BuOK, KOAc and  $K_2CO_3$  were used,  $K_2CO_3$  was the best one among them (Table 1, entries 9−13). To further improve the reaction efficiency, additives such as  $Pd(OAc)_2$ , CuI and  $FeCl<sub>3</sub>$ (10 mol%) were added to the reaction. They suppressed the transformation, and **3a** was obtained in 18%, 20%, and 21%
- 25 yields, respectively (Table 1, entries 14−16). On the other hand, adding TBAB has no influence for this transformation (Table 1, entry 17). Only trace amount of **3a** was detected when TBAI was

**Table 1** Optimization of the reaction conditions*<sup>a</sup>*



*a* Reaction conditions: **1a** (0.50 mmol), **2a** (1.0 mL, as well as solvent), base (0.50 mmol), additive (10 mol%), under air at 145 °C for 16 h. Isolated yield. *<sup>c</sup>* anhydrous *tert*-butyl hydroperoxide was used. DTBP = *tert*-butyl hydroperoxide. CHP = cumyl hydroperoxide. TBAI = 35 tetrabutylammonium iodide. TBAB = tetrabutylammonium bromide.

used as additive (Table 1, entry 18). Notably, further experiment demonstrated a reaction enhancement by using anhydrous TBHP instead of its 70% aqueous solution, providing **3a** in 68% yield (Table 1, entry 19).

With the optimal reaction conditions in hand (in the presence of 4.0 equiv of the anhydrous TBHP at 145 °C for 16 h), the cross-coupling of a diverse range of pyridine *N*-oxides with **2a**  was investigated to probe the generality of this reaction. A series of the corresponding products of pyridine *N*-oxides were then 45 prepared through this cross-coupling reaction and the results are listed in Scheme 4. The reaction is compatible with various electronically and structurally diverse pyridine *N*-oxide derivatives with **2a**, giving the corresponding products in moderate to good yields. Pyridine *N*-oxides with an aryl group 50 (such as Ph, *p*-MeOPh, *p*-(*t*-Bu)Ph, *p*-FPh) on the *para*- or *meta*position reacted with **2a** to generate the cross-coupling products (**3b**, **3c**, **3e**, **3g**, **3h**) in 63−73% yields. It should be noted that 3 naphthylpyridine *N*-oxide also reacted with **2a** smoothly, providing the desired product **3f** in 64% yield. As we expected, <sup>55</sup>*para*- and *meta*-alkyl(alkyloxy) substituted pyridine *N*-oxides also worked well to give the corresponding products (**3d**, **3i**−**k**) in 46−69% yields. In addition, this reaction was applicable to the disubstituted pyridine *N*-oxide, yielding **3l** in 51% yield.

<sup>60</sup>**Scheme 4** Cross-coupling of pyridine *N*-oxides with tetrahydrofuran (THF)*<sup>a</sup>*

| .<br>.  |    |   |            |
|---------|----|---|------------|
| Η.<br>— | 2а | TBHP (4 equiv)<br>$K2CO3$ (1 equiv)<br>145 °C, 16 h | (+<br>За−і |

**Drganic & Biomolecular Chemistry Accepted Manuscript Organic & Biomolecular Chemistry Accepted Manuscript**



Reaction conditions:  $1 (0.50 \text{ mmol})$ ,  $2a (1.0 \text{ mL})$ ,  $K_2CO_3 (0.50 \text{ mmol})$ , TBHP (anhydrous, 2.0 mmol), under air at 145 °C for 16 h. <sup>b</sup> Isolated yield.

Notably, when 3-bromopyridine *N*-oxide was employed, a total 58% yield of the isomer products **3m** and **3m'** was achieved with 20:19 ratio. The C−H activation mainly occurred at the more 5 steric demanding 2-position to afford the product **3m** in 40% yield, and the lower steric demanding 6-position to afford the product **3m**′in 18% yield. Surprisingly, for the substrate in which methyl group located at the *ortho*-position of pyridine *N*oxide, no target product **3n** was obtained.

- The reactions of pyridine *N*-oxides and various ethers were investigated. It can be seen that a range of ethers, such as 1,4 dioxane and tetrahydro-2*H*-pyran participated in the reaction with pyridine *N*-oxide (**1a**), 54−59% yields of the corresponding products (**3o** and **3p**) were achieved as shown in Scheme 5.
- 15 However, the reaction of 2,3-dihydrobenzofuran with **1a**  provided the desired product **3q** only in 34% yield. Simultaneously, in order to expand the scope of pyridine *N*oxides, 3-phenylpyridine1-oxide and 4-phenylpyridine1-oxide were surveyed through the dehydrogenative cross-coupling
- 20 reactions with 1,4-dioxane in the presence of TBHP, which proceeded smoothly to generate the corresponding products **3r** and **3s** in 70% and 65% yields, respectively. It should be noted that there are two kinds of α-position  $C(sp^3)$ –H bonds adjacent to an oxygen atom in 1,3-dioxolane, leading to two region-isomer
- 25 products **3t** and **3t**', in 40:17 ratio. The results indicated that the electronic property of ether influences its regioselectivity. On the other hand, chain ether, such as *tert*-butyl methyl ether was compatible in this transformation, providing the corresponding product **3u** in 59% yield.
- 30

**Scheme 5** The scope of ethers with the reaction of pyridine *N*oxides





*a* Reaction conditions: **1** (0.50 mmol), **2** (1.0 mL), K<sub>2</sub>CO<sub>3</sub> (0.50 mmol), TBHP (anhydrous, 2.0 mmol), under air at 145 °C for 16 h. <sup>*b*</sup> Isolated yield.

With the obtained products, such as **3a**, **3e**, **3f**, **3g** and so on in 35 hand, which were easily reduced under mild conditions. As selected examples (**3a**, **3e**, **3f**, **3g**, **3h**, **3k**, **3l** and **3r**) in Scheme 6, they could be reduced by Zn metal powder and NH<sub>4</sub>Cl (saturated aqueous solution) in  $THF<sup>15</sup>$  to generate the corresponding deoxygenation product pyridines (**4a**, **4e**, **4f**, **4g**, **4h**, **4k**, **4l** and **4r**) 40 in 79−87% yields (Scheme 6).

**Scheme 6** Deoxygenation of 2-(tetrahydrofuran-2-yl)pyridine *N*oxides to 2-(tetrahydrofuran-2-yl)pyridines<sup>4</sup>



NH<sub>4</sub>Cl (saturated aqueous solution, 1.0 mL), THF (1.0 mL), 40 °C for 6 h. <sup>*b*</sup> Isolated yield.

45 When 2,2,6,6-tetramethylpiperidyl-1-oxyl (TEMPO) was added (2.0 equiv) in the model reaction under the present reaction conditions, the reaction was completely shut down. It is suggested that TEMPO acts as a radical scavenger and the reaction involves a radical process.16 A plausible mechanism for 50 this reaction is proposed in Scheme 7. At first, a *tert*-butoxy radical (**I**) and a hydroxyl radical (**II**) were generated from a homolytic cleavage of *tert*-butyl hydroperoxide (TBHP). Then  $45$ 

THF (**2a**) underwent a hydrogen abstraction of C−H bond adjacent to its oxygen atom in the presence of **I** or/and **II** to get the corresponding free radical **A**. Addition of **A** to pyridine *N*oxide generated the radical **B**. 17 Finally, the desired product **3a** 5 was formed through the reaction of the intermediate **B** with **I** or/and **II**. The proposed mechanism was further investigated through the trapping of free radical **A** with TEMPO by HPLC-HRMS probe. The coupling product of **A** with TEMPO was confirmed by HRMS.

**Scheme 7** The proposed reaction mechanism



In summary, we have developed a novel and efficient method 15 for the preparation of biheterocycles from pyridine *N*-oxides and simple ethers via intermolecular dehydrogenative reaction between between  $C(sp^2)$ -H/C(sp<sup>3</sup>)-H bond in the presence of TBHP. Moreover, the obtained 2-substituted pyridine *N*-oxides could be reduced to the 2-substituted pyridines under mild 20 reduction conditions. This strategy provides an alternative approach to 2-substituted pyridine moiety under transition-metalfree conditions. The detail mechanism investigation and further application of this protocol is underway in our laboratory.

25

10

### **Experimental Section**

All operations are carried out in a glove box under nitrogen atmosphere. All  ${}^{1}$ H NMR and  ${}^{13}$ C NMR spectra were recorded on a 400 MHz Bruker FT-NMR spectrometers (400 MHz or 100

- 30 MHz, respectively). All chemical shifts are given as δ value (ppm) with reference to tetramethylsilane (TMS) as an internal standard. The peak patterns are indicated as follows: s, singlet; d, doublet; t, triplet; m, multiplet; q, quartet. The coupling constants, J, are reported in Hertz (Hz). High resolution mass spectroscopy data of
- 35 the product were collected on a Waters Micromass GCT instrument. High resolution mass spectroscopy data of the product were collected on an Agilent Technologies 6540 UHD Accurate-Mass Q-TOF LC/MS (ESI).

The chemicals and solvents were purchased from commercial 40 suppliers either from Aldrich (USA) or Shanghai Chemical Company (China) without further purification. All the solvents were dried and freshly distilled prior to use. All the reactions

### *Typical procedure for the cross-coupling of pyridine 1-oxide with tetrahydrofuran*

 To a 25 mL Schlenk tube were added pyridine 1-oxide (0.50 mmol), anhydrous *tert*-butyl hydroperoxide (TBHP, 2.0 mmol,  $50 \text{ } 4.0 \text{ }$  equiv) and  $K_2CO_3$  (0.50 mmol, 1.0 equiv). Then tetrahydrofuran (THF, 1.0 mL) was injected into bottom of the tube using a long needle syringe. The mixture was stirred at the preheated oil bath under 140 °C for 16 h. When the reaction was cooled down to room temperature, the mixture was filtered 55 through a short plug of silica gel and washed with ethyl ether  $(3\times6.0$  mL) and saturated NaCl solution  $(3\times6.0$  mL). The combined organic phase was dried over MgSO<sub>4</sub> and then concentrated under vacuum. The product was purified through flash column chromatography on 200–300 mesh silica gel with 60 petroleum ether/ethyl acetate as eluent with a suitable ratio according to the TLC analysis.

### *General procedure for deoxidizative reaction*

 According to the procedure reported in the literature (Y. 65 Aoyagi, T. Abe and A. Ohta, *Synthesis,* 1997, 891), a 20 mL vial was charged with 2-substituted pyridine *N*-oxide (0.30 mmol, 1.0 equiv), THF (1.0 mL) and saturated NH<sub>4</sub>Cl aqueous solution (1.0 mL). After the mixture was stirred under an air atmosphere at 40  $^{\circ}$ C for 30 minutes,  $Zn^0$  powder (0.90 mmol, 3.0 equiv) in 4 70 portions of 0.75 eq. each in 20 minutes interval was added. When the reaction was complete by TLC analysis, the mixture was filtered to remove unreacted  $Zn^0$  and filter cake was washed with THF. The mixture was diluted with EtOAc and organic layer was separated. The organic phase was washed with  $H_2O$  (2×5.0 mL), 75 dried with MgSO4, filtered and concentrated in vacuo. The

residue is then purified via silica gel chromatography using petroleum ether/ethyl acetate mixtures.



#### 80 **2-(Tetrahydrofuran-2-yl)pyridine 1-oxide (3a)**

Colourless liquid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 8.22 (d,  $J =$ 6.32 Hz, 1H), 7.53 (d, *J* = 7.68 Hz, 1H), 7.32–7.28 (m, 1H), 7.21– 7.17 (m, 1H), 5.36 (t, *J* = 6.42 Hz, 1H), 4.13–4.08 (m, 1H), 4.00– 85 3.94 (m, 1H), 2.75–2.66 (m, 1H), 2.07–1.99 (m, 1H), 1.92–1.81 (m, 2H); 13C NMR (100 Mz, CDCl3) δ: 139.4, 126.2, 123.8, 122.5, 75.3, 69.1, 30.9, 25.6. HRMS (ESI) ([M+H]<sup>+</sup>) Calcd. For C<sub>9</sub>H<sub>12</sub>NO<sub>2</sub>: 166.0868, Found: 166.0868.



### 90 **5-Phenyl-2-(tetrahydrofuran-2-yl)pyridine 1-oxide (3b)** Yellow liquid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 8.49 (s, 1H), 7.58-7.56 (m, 1H), 7.54–7.51 (m, 3H), 7.49–7.41 (m, 4H), 5.40 (t, *J* = 6.04 Hz, 1H), 4.14–4.11 (m, 1H), 4.01–3.96 (m, 1H), 2.76–2.70

were carried out under air atmosphere. Products were purified by flash chromatography on  $100-200$  mesh silica gels,  $SiO<sub>2</sub>$ .

**<sup>4</sup>** | *Journal Name*, [year], **[vol]**, 00–00 **This journal is © The Royal Society of Chemistry [year]** 

 $(m, 1H)$ , 2.04 (br, 1H), 1.90 (br, 2H); <sup>13</sup>C NMR (100 Mz, CDCl<sub>3</sub>) δ: 152.2, 138.1, 137.6, 135.3, 129.2, 129.0, 126.8, 125.0, 122.4, 75.3, 69.1, 31.0, 25.6. HRMS (ESI) ([M+H]+) Calcd. For  $C_{15}H_{15}NO_2$ : 242.1181, Found: 242.1179. HRMS (ESI) ([M+H]<sup>+</sup>) 5 Calcd. For C15H16NO2: 242.1181, Found: 242.1179.



### **4-Phenyl-2-(tetrahydrofuran-2-yl)pyridine 1-oxide (3c)**

Yellow liquid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 8.24 (d,  $J = 6.72$ 10 Hz, 1H), 7.75 (s, 1H), 7.62 (d, *J* = 7.60 Hz, 2H), 7.49–7.46 (m, 2H), 7.43–7.40 (m, 2H), 5.39 (t, *J* = 6.44 Hz, 1H), 4.18–4.12 (m, 1H), 4.02–3.97 (m, 1H), 2.80–2.72 (m, 1H), 2.09–2.01 (m, 1H), 1.96–1.85 (m, 2H); 13C NMR (100 Mz, CDCl3) δ: 153.7, 139.4, 138.7, 136.8, 129.2, 128.9, 126.5, 121.5, 120.0, 75.4, 69.1, 31.0, 15 25.6. HRMS (ESI) ( $[M+H]^+$ ) Calcd. For C<sub>15</sub>H<sub>16</sub>NO<sub>2</sub>: 242.1181, Found: 242.1176.



### **4-Methoxy-2-(tetrahydrofuran-2-yl)pyridine 1-oxide (3d)**

 $_{20}$  Colourless liquid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 8.08 (d, *J* = 6.84 Hz, 1H), 7.03 (s, 1H), 6.70–6.69 (m, 1H), 5.31 (br, 1H), 4.09–4.08 (m, 1H), 3.95–3.94 (m, 1H), 3.84 (s, 3H), 2.72–2.71 (m, 1H), 2.00 (br, 1H), 1.85 (br, 2H); 13C NMR (100 Mz, CDCl3) δ: 158.1, 154.8, 140.2, 110.4, 107.2, 75.4, 69.1, 55.9, 31.0, 25.5. 25 HRMS (ESI) ( $[M+H]^+$ ) Calcd. For C<sub>10</sub>H<sub>14</sub>NO<sub>3</sub>: 196.0974, Found: 196.0971.



**5-(4-Methoxyphenyl)-2-(tetrahydrofuran-2-yl)pyridine 1-** <sup>30</sup>**oxide (3e)**

- White solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 8.41 (s, 1H), 7.52 (d, *J* = 8.24 Hz, 1H), 7.47–7.41 (m, 3H), 6.98 (d, *J* = 8.56 Hz, 2H), 5.39 (t, *J* = 5.82 Hz, 1H), 4.15–4.10 (m, 1H), 4.00–3.94 (m, 1H), 3.84 (s, 3H), 2.73–2.68 (m, 1H), 2.06–1.99 (m, 1H), 1.92–1.83
- 35 (m, 2H); <sup>13</sup>C NMR (100 Mz, CDCl<sub>3</sub>) δ: 160.3, 137.6, 137.1, 127.9, 127.6, 124.3, 122.2, 114.6, 75.2, 69.1, 55.3, 31.0, 25.5. HRMS (ESI)  $([M+H]^+)$  Calcd. For  $C_{16}H_{18}NO_3$ : 272.1287, Found: 272.1285.



**5-(Naphthalen-2-yl)-2-(tetrahydrofuran-2-yl)pyridine 1-oxide (3f)**

Colourless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 8.60 (s, 1H), 8.01 (s, 1H), 7.96 (d, *J* = 8.52 Hz, 1H), 7.92–7.88 (m, 2H), 7.64

- 45 (dd,  $J_1 = 8.56$  Hz,  $J_2 = 1.28$  Hz, 1H), 7.61 (br, 2H), 7.57–7.53 (m, 2H), 5.46–5.43 (m, 1H), 4.19–4.14 (m, 1H), 4.04–3.99 (m, 1H), 2.80–2.71 (m, 1H), 2.11–2.03 (m, 1H), 1.98–1.88 (m, 2H); 13C
- NMR (100 Mz, CDCl3) δ: 152.3, 138.0, 137.8, 133.4, 133.2, 132.6, 129.2, 128.3, 127.7, 126.9, 126.8, 126.2, 124.8, 124.2, 50 122.5, 75.4, 69.2, 31.0, 25.6. HRMS (ESI) ([M+H]<sup>+</sup>) Calcd. For  $C_{19}H_{18}NO_2$ : 292.1338, Found: 292.1335.



### **5-(4-(***tert***-Butyl)phenyl)-2-(tetrahydrofuran-2-yl)pyridine 1-** <sup>55</sup>**oxide (3g)**

- White solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 8.47 (s, 1H), 7.56 (d, *J* = 8.24 Hz, 1H), 7.52–7.47 (m, 5H), 5.43–5.39 (m, 1H), 4.17– 4.11 (m, 1H), 4.02–3.97 (m, 1H), 2.76–2.71 (m, 1H), 2.10–2.01 (m, 1H), 1.97–1.90 (m, 2H), 1.36 (s, 9H); 13C NMR (100 Mz,
- 60 CDCl3) δ: 152.3, 151.9, 137.9, 137.4, 132.4, 126.5, 126.2, 124.6, 122.3, 75.3, 69.1, 34.7, 31.2, 31.0, 25.6. HRMS (ESI) ([M+H]+ ) Calcd. For C<sub>19</sub>H<sub>24</sub>NO<sub>2</sub>: 298.1807, Found: 298.1803.



<sup>65</sup>**5-(4-Fluorophenyl)-2-(tetrahydrofuran-2-yl)pyridine 1-oxide** (**3h)** 

Yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 8.41 (s, 1H), 7.56 (d, *J* = 8.20 Hz, 1H), 7.51–7.48 (m, 2H), 7.42 (d, *J* = 8.20 Hz, 1H), 7.18–7.14 (m, 2H), 5.38 (t, *J* = 6.38 Hz, 1H), 4.15–4.10 (m, 1H), 70 4.01–3.95 (m, 1H), 2.75–2.69 (m, 1H), 2.11–2.00 (m, 1H), 1.95– 1.84 (m, 2H); <sup>13</sup>C NMR (100 Mz, CDCl<sub>3</sub>) δ: 163.3 (d,  $J_{C-F}$  = 247.91 Hz), 152.3, 137.4, 137.1, 131.5 (d, *JC-F* = 3.41 Hz), 128.6 (d, *JC-F* = 8.31 Hz), 124.4, 122.5, 116.3 (d, *JC-F* = 21.74 Hz), 75.3,

69.1, 31.0, 25.6. HRMS (ESI)  $([M+H]^+)$  Calcd. For  $C_{15}H_{15}FNO_2$ : 75 260.1087, Found: 260.1087.



### **4-Methyl-2-(tetrahydrofuran-2-yl)pyridine 1-oxide (3i)**

Colourless liquid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 8.08 (d,  $J =$ 80 6.52 Hz, 1H), 7.31 (s, 1H), 6.97–6.96 (m, 1H), 5.33 (t, *J* = 6.60 Hz, 1H), 4.12–4.07 (m, 1H), 3.98–3.92 (m, 1H), 2.74–2.65 (m, 1H), 2.34 (s, 3H), 2.06–1.96 (m, 1H), 1.92–1.78 (m, 2H); <sup>13</sup>C NMR (100 Mz, CDCl<sub>3</sub>) δ: 153.0, 138.7, 137.6, 124.5, 123.0, 75.3, 69.1, 31.0, 25.6, 20.5. HRMS (ESI) ([M+H]<sup>+</sup>) Calcd. For 85 C10H14NO2: 180.1025, Found: 180.1025.



### **5-Methyl-2-(tetrahydrofuran-2-yl)pyridine 1-oxide (3j)**  Colourless liquid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 8.06 (s, 1H), 90 7.38 (d, *J* = 8.08 Hz, 1H), 7.10 (d, *J* = 8.04 Hz, 1H), 5.33 (t, *J* =

This journal is © The Royal Society of Chemistry [year] Journal Name, [year], **[vol]**, 00–00 | **5**

6.48 Hz, 1H), 4.11–4.06 (m, 1H), 3.97–3.92 (m, 1H), 2.72–2.62 (m, 1H), 2.28 (s, 3H), 2.05–1.95 (m, 1H), 1.91–1.78 (m, 2H); 13C NMR (100 Mz, CDCl3) δ: 151.0, 139.2, 134.3, 127.3, 121.9, 75.3, 69.0, 31.0, 25.5, 17.9. HRMS (ESI) ([M+H]<sup>+</sup>) Calcd. For  $5 \text{ C}_{10}H_{14}NO_2$ : 180.1025, Found: 180.1024.



**4-Ethyl-2-(tetrahydrofuran-2-yl)pyridine 1-oxide (3k)** 

Yellow liquid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 8.11 (d, *J* = 6.52 10 Hz, 1H), 7.33 (s, 1H), 7.00 (d, *J* = 5.16 Hz, 1H), 5.35 (t, *J* = 6.46 Hz, 1H), 4.14–4.09 (m, 1H), 4.00–3.94 (m, 1H), 2.76–2.70 (m, 1H), 2.65 (q, *J* = 7.53 Hz, 2H), 2.07–1.97 (m, 1H), 1.93–1.80 (m, 2H), 1.25 (t, *J* = 7.54 Hz, 3H); 13C NMR (100 Mz, CDCl3) δ: 153.1, 143.6, 138.9, 123.2, 121.7, 75.3, 69.1, 30.9, 27.7, 25.6, 15 14.3. HRMS (ESI) ( $[M+H]^+$ ) Calcd. For C<sub>11</sub>H<sub>16</sub>NO<sub>2</sub>: 194.1181, Found: 194.1183.



**3,5-Dimethyl-2-(tetrahydrofuran-2-yl)pyridine 1-oxide (3l)**  <sup>20</sup> Colourless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 7.94 (s, 1H), 6.85 (s, 1H), 5.73 (t, *J* = 7.92 Hz, 1H), 4.10–4.04 (m, 1H), 3.93– 3.88 (m, 1H), 2.56–2.48 (m, 1H), 2.39 (s, 3H), 2.21 (s, 3H), 2.10– 2.00 (m, 2H), 1.93–1.83 (m, 1H); <sup>13</sup>C NMR (100 Mz, CDCl<sub>3</sub>) δ: 148.0, 137.4, 134.6, 133.2, 130.7, 75.5, 68.5, 29.9, 26.6, 18.9,

25 17.6. HRMS (ESI) ( $[M+H]^+$ ) Calcd. For C<sub>11</sub>H<sub>16</sub>NO<sub>2</sub>: 194.1181, Found: 194.1180.



### **3-Bromo-2-(tetrahydrofuran-2-yl)pyridine 1-oxide (3m)**

Yellow liquid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 7.38 (d,  $J = 5.96$ 30 Hz, 1H), 7.20–7.17 (m, 2H), 5.37 (t, *J* = 6.72 Hz, 1H), 4.12–4.07 (m, 1H), 3.98–3.93 (m, 1H), 2.75–2.66 (m, 1H), 2.05–1.95 (m, 1H), 1.91–1.78 (m, 2H); <sup>13</sup>C NMR (100 Mz, CDCl<sub>3</sub>) δ: 153.8, 148.9, 125.2, 124.2, 120.0, 75.6, 69.0, 31.0, 25.6. HRMS (ESI)  $([M+H]^+)$  Calcd. For  $C_9H_{11}BrNO_2$ : 243.9973, Found: 243.9972.



35

**5-Bromo-2-(tetrahydrofuran-2-yl)pyridine 1-oxide (3 m′)** Yellow liquid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 8.33 (s, 1H), 7.38

(br, 2H), 5.24 (t, *J* = 6.42 Hz, 1H), 4.10–4.05 (m, 1H), 3.97–3.91 40 (m, 1H), 2.71–2.61 (m, 1H), 2.06–1.95 (m, 1H), 1.89–1.76 (m, 2H); 13C NMR (100 Mz, CDCl3) δ: 153.0, 140.6, 128.6, 122.8, 117.9, 75.1, 69.1, 30.7, 25.5. HRMS (ESI) ([M+H]<sup>+</sup>) Calcd. For C<sub>9</sub>H<sub>11</sub>BrNO<sub>2</sub>: 243.9973, Found: 243.9966.



45

**2-(1,4-Dioxan-2-yl)pyridine 1-oxide (3o)** 

Colourless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 8.19 (d,  $J = 6.36$ Hz, 1H), 7.56 (d, *J* = 7.76 Hz, 1H), 7.32–7.29 (m, 1H), 7.23–7.19 (m, 1H), 5.31–5.28 (m, 1H), 4.52–4.83 (m, 1H), 3.97 (d, *J* = 6.24 50 Hz, 2H), 3.84–3.81 (m, 1H), 3.75–3.67 (m, 1H), 3.24–3.19 (m, 1H); 13C NMR (100 Mz, CDCl3) δ: 148.9, 139.3, 125.9, 124.5,

123.9, 72.2, 68.6, 67.2, 66.4. HRMS (ESI) ([M+H]<sup>+</sup>) Calcd. For C9H12NO3: 182.0817, Found: 182.0815.



### **2-(Tetrahydro-2H-pyran-2-yl)pyridine 1-oxide (3p)**

Colourless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 8.19 (d,  $J = 6.40$ Hz, 1H), 7.55 (dd, *J* = 7.84 Hz, *J* = 1.44 Hz, 1H), 7.31–7.30 (m, 1H), 7.19–7.15 (m, 1H), 5.00–4.98 (m, 1H), 4.18–4.15 (m, 1H), 60  $3.71-3.65$  (m, 1H),  $2.45-2.42$  (m, 1H),  $1.94-1.91$  (m, 1H),  $1.82-$ 1.79 (m, 2H), 1.64–1.61 (m, 1H), 1.26–1.20 (m, 1H); <sup>13</sup>C NMR (100 Mz, CDCl3) δ: 139.2, 126.0, 123.7, 123.1, 73.7, 68.9, 29.6, 25.9, 23.1. HRMS (ESI)  $([M+H]^+)$  Calcd. For C<sub>10</sub>H<sub>14</sub>NO<sub>2</sub>: 180.1025, Found: 108.1028.



## **2-(2,3-Dihydrobenzofuran-2-yl)pyridine 1-oxide (3q)**

Yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 8.28 (d,  $J = 6.12$  Hz, 1H), 7.54 (dd, *J*<sup>1</sup> = 7.72 Hz, *J*<sup>2</sup> = 1.28 Hz, 1H), 7.32–7.28 (m, 1H), 70 7.26–7.23 (m, 1H), 7.20–7.17 (m, 2H), 6.96 (d, *J* = 8.28 Hz, 1H), 6.93–6.90 (m, 1H), 6.20–6.16 (m, 1H), 4.04–3.97 (m, 1H), 3.19– 3.13 (m, 1H); 13C NMR (100 Mz, CDCl3) δ: 159.0, 139.5, 128.2, 126.1, 125.9, 125.3, 124.4, 122.7, 121.4, 109.5, 78.0, 35.5. HRMS (ESI)  $([M+H]^+)$  Calcd. For  $C_{13}H_{12}NO_2$ : 214.0868, Found: 75 214.0861.



### **2-(1,4-Dioxan-2-yl)-5-phenylpyridine 1-oxide (3r)**

Colourless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 8.44 (s, 1H), 80 7.60 (d, *J* = 8.24 Hz, 1H), 7.53–7.44 (m, 6H), 5.36–5.33 (m, 1H), 4.56–4.52 (m, 1H), 3.99 (d, *J* = 6.12 Hz, 2H), 3.86–3.83 (m, 1H),  $3.77-3.68$  (m, 1H),  $3.29-3.24$  (m, 1H); <sup>13</sup>C NMR (100 Mz, CDCl3) δ: 147.1, 138.7, 137.4, 135.1, 129.3, 129.1, 126.8, 124.5, 123.7, 72.2, 68.7, 67.2, 66.4. HRMS (ESI) ([M+H]<sup>+</sup>) Calcd. For 85 C<sub>15</sub>H<sub>16</sub>NO<sub>3</sub>: 258.1130, Found: 258.1124.



### **2-(1,4-Dioxan-2-yl)-4-phenylpyridine 1-oxide (3s)**

White solid. <sup>1</sup> H NMR (400 MHz, CDCl3) δ: 8.23 (d, *J* = 6.76 Hz, 90 1H), 7.81–7.80 (m, 1H), 7.63 (d, *J* = 7.32 Hz, 2H), 7.51–7.47 (m, 2H), 7.45–7.41 (m, 2H), 5.36–5.34 (m, 1H), 4.58–4.55 (m, 1H), 4.01 (d, *J* = 6.12 Hz, 2H), 3.87–3.84 (m, 1H), 3.79–3.71 (m, 1H), 3.31–3.26 (m, 1H); <sup>13</sup>C NMR (100 Mz, CDCl<sub>3</sub>) δ: 148.7, 139.3, 138.7, 136.5, 129.2, 129.0, 126.5, 122.1, 121.5, 72.4, 68.8, 67.3, 95 66.5. HRMS (ESI) ( $[M+H]^+$ ) Calcd. For C<sub>15</sub>H<sub>16</sub>NO<sub>3</sub>: 258.1130, Found: 258.1127.

**6** | *Journal Name*, [year], **[vol]**, 00–00 **This journal is © The Royal Society of Chemistry [year]** 



### **2-(1,3-Dioxolan-4-yl)pyridine 1-oxide (3t)**

Yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 8.19 (d, *J* = 6.48 Hz, 5 1H), 7.52 (d, *J* = 7.80 Hz, 1H), 7.32–7.29 (m, 1H), 7.24–7.20 (m, 1H), 5.40 (d, *J* = 6.16 Hz, 1H), 5.20 (s, 1H), 5.03 (s, 1H), 4.48– 4.44 (m, 1H), 3.93–3.90 (m, 1H); 13C NMR (100 Mz, CDCl3) δ: 150.9, 139.0, 125.9, 124.4, 122.6, 95.5, 70.8 (d,  $J = 232.18$  Hz), 65.4 (d,  $J = 13.83$  Hz). HRMS (ESI) ( $[M+H]^+$ ) Calcd. For 10 C<sub>8</sub>H<sub>10</sub>NO<sub>3</sub>: 168.0661, Found: 168.0665.



### **2-(1,3-Dioxolan-2-yl)pyridine 1-oxide (3t')**

Yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 8.24–8.22 (m, 1H), 15 7.56–7.54 (m, 1H), 7.26 (br, 2H), 6.36 (s, 1H), 4.09 (br, 4H);  $^{13}$ C NMR (100 Mz, CDCl<sub>3</sub>) δ: 147.5, 139.8, 125.8, 125.3, 123.6, 97.3, 65.4. HRMS (ESI) ( $[M+H]^+$ ) Calcd. For C<sub>8</sub>H<sub>10</sub>NO<sub>3</sub>: 168.0661, Found: 168.0658.



### **2-(***tert***-Butoxymethyl)pyridine 1-oxide (3u)**

Colourless liquid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 8.23 (br, 1H), 7.61 (d, *J* = 7.00 Hz, 1H), 7.30–7.27 (m, 1H), 7.18 (br, 1H), 4.71 (s, 2H), 1.31 (s, 9H); <sup>13</sup>C NMR (100 Mz, CDCl<sub>3</sub>) δ: 138.8, 125.8,

25 123.4, 123.3, 74.3, 58.8, 27.5. HRMS (ESI) ([M+H]<sup>+</sup>) Calcd. For C10H16NO2: 182.1181, Found: 182.1179.



### **2-(Tetrahydrofuran-2-yl)pyridine (4a)**

30 Colourless liquid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 8.52 (d, *J* = 3.36 Hz, 1H), 7.66–7.62 (m, 1H), 7.41 (d, *J* = 7.80 Hz, 1H), 7.14– 7.11 (m, 1H), 5.00 (t, *J* = 6.06 Hz, 1H), 4.11–4.06 (m, 1H), 3.98– 3.93 (m, 1H), 2.41–2.38 (m, 1H), 1.97–1.96 (m, 3H); <sup>13</sup>C NMR (100 Mz, CDCl3) δ: 162.9, 148.9, 136.5, 121.9, 119.7, 81.2, 68.9, 35 32.9, 25.7. HRMS (ESI)  $([M+H]^+)$  Calcd. For C<sub>9</sub>H<sub>12</sub>NO: 150.0919, Found: 150.0921.



**5-(4-Methoxyphenyl)-2-(tetrahydrofuran-2-yl)pyridine (4e)**  40 White solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 8.75 (s, 1H), 7.82 (d, *J* = 8.00 Hz, 1H), 7.52–7.47 (m, 3H), 7.01 (d, *J* = 8.20 Hz, 2H), 5.07 (t, *J* = 6.16 Hz, 1H), 4.16–4.11 (m, 1H), 4.03–3.98 (m, 1H), 3.86 (s, 3H), 2.49–2.39 (m, 1H), 2.09–2.00 (m, 3H); 13C NMR (100 Mz, CDCl3) δ: 161.0, 159.6, 147.1, 134.6, 134.4, 130.2,

45 128.1, 119.7, 114.5, 81.2, 69.0, 55.3, 33.0, 25.8. HRMS (ESI)  $([M+H]^+)$  Calcd. For  $C_{16}H_{18}NO_2$ : 256.1338, Found: 256.1340.



### **5-(Naphthalen-2-yl)-2-(tetrahydrofuran-2-yl)pyridine (4f)**

50 White solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 8.92 (s, 1H), 8.05 (s, 1H), 8.02–7.89 (m, 4H), 7.72 (d, *J* = 8.36 Hz, 1H), 7.58–7.53 (m, 3H), 5.14–5.10 (m, 1H), 4.20–4.15 (m, 1H), 4.06–4.01 (m, 1H), 2.53–2.47 (m, 1H), 2.13–2.03 (m, 3H); <sup>13</sup>C NMR (100 Mz, CDCl3) δ: 161.9, 147.7, 135.2, 135.1, 135.0, 133.6, 132.8, 128.8,

55 128.2, 127.7, 126.6, 126.3, 126.0, 125.1, 119.8, 81.2, 69.1, 33.1, 25.8. HRMS (ESI) ([M+H]<sup>+</sup>) Calcd. For C<sub>19</sub>H<sub>18</sub>NO: 276.1388, Found: 276.1393.



- <sup>60</sup>**5-(4-(***tert***-Butyl)phenyl)-2-(tetrahydrofuran-2-yl)pyridine (4g)**  Colourless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 8.79 (s, 1H), 7.87 (d, *J* = 7.88 Hz, 1H), 7.55–7.50 (m, 5H), 5.08 (t, *J* = 6.46 Hz, 1H), 4.18–4.12 (m, 1H), 4.04–3.99 (m, 1H), 2.52–2.41 (m, 1H), 2.11–2.01 (m, 3H), 1.38 (s, 9H); <sup>13</sup>C NMR (100 Mz, CDCl<sub>3</sub>) δ: 65 161.4, 151.0, 147.4, 134.9, 134.8, 134.8, 126.7, 126.0, 119.8,
- 81.2, 69.1, 34.6, 33.0, 31.3, 25.8. HRMS (ESI) ( $[M+H]^+$ ) Calcd. For C19H24NO: 282.1858, Found: 282.1856.



<sup>70</sup>**5-(4-Fluorophenyl)-2-(tetrahydrofuran-2-yl)pyridine (4h)**  Colourless liquid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 8.73 (s, 1H), 7.83 (d, *J* = 8.08 Hz, 1H), 7.56–7.51 (m, 3H), 7.19–7.15 (m, 2H), 5.08 (t, *J* = 6.32 Hz, 1H), 4.17–4.12 (m, 1H), 4.04–3.99 (m, 1H), 2.50–2.41 (m, 1H), 2.09–1.98 (m, 3H); <sup>13</sup>C NMR (100 Mz, 75 CDCl3) δ: 162.8 (d, *JC-F* = 247.82 Hz), 161.8, 147.3, 134.8, 134.0  $(d, J_{C-F} = 17.60 \text{ Hz})$ , 128.7 (dd,  $J_{C-F} = 8.07 \text{ Hz}$ ,  $J_{C-F} = 1.90 \text{ Hz}$ ), 119.8 (d, *JC-F* = 1.84), 116.1, 115.9 (d, *JC-F* = 1.89 Hz), 81.1, 69.1 (d,  $J_{C-F}$  = 1.80 Hz), 33.0 (d,  $J_{C-F}$  = 1.78 Hz), 25.8 (d,  $J_{C-F}$  = 1.89 Hz). HRMS (ESI)  $([M+H]^+)$  Calcd. For  $C_{15}H_{15}FNO: 244.1138$ , 80 Found: 244.1132.



### **4-Ethyl-2-(tetrahydrofuran-2-yl)pyridine (4k)**

Colourless liquid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 8.38 (d,  $J =$ 85 4.84 Hz, 1H), 7.24 (s, 1H), 6.95 (d, *J* = 4.60 Hz, 1H), 4.95 (t, *J* = 6.30 Hz, 1H), 4.10–4.04 (m, 1H), 3.96–3.90 (m, 1H), 2.60 (q, *J* = 7.59 Hz, 2H), 2.43–2.32 (m, 1H), 1.94 (br, 3H), 1.20 (q, *J* = 7.58 Hz, 3H); 13C NMR (100 Mz, CDCl3) δ: 162.6, 153.5, 148.8, 121.6, 119.2, 81.2, 68.8, 32.9, 28.2, 25.6, 14.2. HRMS (ESI) 90 ( $[M+H]^+$ ) Calcd. For C<sub>11</sub>H<sub>16</sub>NO: 178.1232, Found: 178.1234.

This journal is © The Royal Society of Chemistry [year] Journal Name, [year], **[vol]**, 00–00 | **7**

**Organic & Biomolecular Chemistry Accepted Manuscript**ganic & Biomolecular Chemistry Accepted Manuscript



### **3,5-Dimethyl-2-(tetrahydrofuran-2-yl)pyridine (4l)**

Yellow liquid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 8.26 (s, 1H), 7.25  $(s, 1H), 5.10$  (t,  $J = 7.08$  Hz, 1H), 4.15–4.10 (m, 1H), 3.94–3.89 5 (m, 1H), 2.34 (s, 3H), 2.27 (s, 3H), 2.24–2.17 (m, 2H), 2.15–2.09 (m, 1H), 2.06–1.96 (m, 1H); <sup>13</sup>C NMR (100 Mz, CDCl<sub>3</sub>) δ: 155.5, 147.0, 138.8, 131.6, 130.5, 78.4, 68.6, 30.5, 26.2, 18.2, 17.9. HRMS (ESI)  $([M+H]^+)$  Calcd. For  $C_{11}H_{16}NO$ : 178.1232, Found: 178.1231.



### **2-(1,4-Dioxan-2-yl)-5-phenylpyridine (4r)**

White solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 8.79 (s, 1H), 7.91 (d, *J* = 7.92 Hz, 1H), 7.58 (d, *J* = 7.48 Hz, 2H), 7.54 (d, *J* = 8.12 Hz, 15 1H), 7.51–7.47 (m, 2H), 7.43–7.40 (m, 1H), 4.83–4.80 (m, 1H),

4.21–4.18 (m, 1H), 4.03–3.95 (m, 2H), 3.86–3.75 (m, 2H), 3.62– 3.57 (m, 1H); <sup>13</sup>C NMR (100 Mz, CDCl<sub>3</sub>) δ: 156.6, 147.5, 137.6, 135.8, 135.1, 129.1, 128.1, 127.1, 120.7, 78.0, 71.2, 67.0, 66.4. HRMS (ESI) ( $[M+H]^+$ ) Calcd. For C<sub>15</sub>H<sub>16</sub>NO<sub>2</sub>: 242.1181, Found: 20 242.1185.

### **Acknowledgements**

This work was financially supported by the National Science Foundation of China (No. 21372095 and 21172092).

*<sup>a</sup>* <sup>25</sup>*Department of Chemistry, Huaibei Normal University, Huaibei, Anhui 235000 (P.R. China); E-mail: leiwang@chnu.edu.cn b*

 *State Key Laboratory of Organometallic Chemistry, Shanghai Institute of Organic Chemistry, Shanghai 200032 (P.R. China)* 

† Electronic Supplementary Information (ESI) available: [details of any 30 supplementary information available should be included here].

### **Notes and reference**

- 1 (*a*) P. Xi, F. Yang, S. Qin, D. Zhao, J. Lan, G. Gao, C. Hu and J. You, *J. Am. Chem. Soc.,* 2010, **132**, 1822; (*b*) Z. Wu, C. Pi, X. Cui, J. Bai and Y. Wu, *Adv. Synth. Catal.,* 2013, **355**, 1971.
- 35 2 (*a*) J. A. J. Bull, J. J. Mousseau, G. Pelletier and A. B. Charette, *Chem. Rev.,* 2012, **112**, 2642; (*b*) L.-C. Campeau, S. Rousseaux and K. Fagnou, *J. Am. Chem. Soc.,* 2005, **127**, 18020; (*c*) L.-C. Campeau, D. R. Stuart, J.-P. Leclerc, M. Bertrand-Laperle, E. Villemure, H.-Y. Sun, S. Lasserre, N. Guimond, M. Lecavallier and K. Fagnou, *J. Am. Chem.*
- <sup>40</sup>*Soc.,* 2009, **131**, 3291; (*d*) S. H. Cho, S. J. Hwang and S. Chang, *J. Am. Chem. Soc.,* 2008, **130**, 9254; (*e*) Z. Wang, K. Li, D. Zhao, J. Lan and J. You, *Angew. Chem., Int. Ed.,* 2011, **50**, 5365.
- 3 (*a*) Y. Tan, F. Barrios-Landeros and J. F. Hartwig, *J. Am. Chem. Soc.,* 2012, **134**, 3683; (*b*) F. Gosselin, S. J. Savage, N. Blaquiere and S. T.
- 45 Staben, *Org. Lett.,* 2012, **14**, 862; (*c*) S. Duric and C. C. Tzschucke, *Org. Lett.,* 2011, **13**, 2310; (*d*) D. Zhao, W. Wang, F. Yang, J. Lan, L. Yang, G. Gao and J. You, *Angew. Chem., Int. Ed.,* 2009, **48**, 3296.
- 4 (*a*) W. Mai, J. Yuan, Z. Li, L. Yang, Y. Xiao, P. Mao and L. Qu, *Synlett,* 2012, **23**, 938; (*b*) B. Xiao, Z.-J. Liu, L. Liu and Y. Fu, *J. Am.*
- <sup>50</sup>*Chem. Soc.,* 2013, **135**, 616; (*c*) B. Yao, R.-J. Song, Y. Liu, Y.-X. Xie, J.-H. Li, M.-K. Wang, R.-Y. Tang, X.-G. Zhang and C.-L. Deng, *Adv. Synth. Catal.,* 2012, **354**, 1890.
- 5 J. Wu, X. Cui, L. Chen, G. Jiang and Y. Wu, *J. Am. Chem. Soc.,* 2009, **131**, 13888.
- 55 6 S. E. Wengryniuk, A. Weickgenannt, C. Reiher, N. A. Strotman, K. Chen, M. D. Eastgate and P. S. Baran, *Org. Lett.,* 2013, **15**, 792.
- 7 (*a*) J. M. Keith, *J. Org. Chem.,* 2010, **75**, 2722; (*b*) J. Yin, B. Xiang, M. A. Huffman, C. E. Raab and I. W. Davies, *J. Org. Chem.,* 2007, **72**, 4554.
- 60 8 (*a*) N. Kuhl, M. N. Hopkinson, J. Wencel-Delord and F. Glorius, *Angew. Chem. Int. Ed.,* 2012, **51**, 10236; (*b*) D. Zhao, J. You and C. Hu, *Chem.*-*Eur. J.,* 2011, **17**, 5466; (*c*) Anastas, P. T and J. C. Warner, *Green Chemistry: Theory and Practice*, Oxford University Press, New York, 1998; (*d*) G. P. McGlacken and L. M. Bateman,
- <sup>65</sup>*Chem. Soc. Rev.,* 2009, **38**, 2447; (*e*) A. Armstrong and J. C. Collins, *Angew. Chem., Int. Ed.,* 2010, **49**, 2282; (*f*) C.-L. Sun, B.-J. Li and Z.- J. Shi, *Chem. Rev.,* 2011, **111**, 1293; (*g*) B. Yao, C.-L. Deng, Y. Liu, R.-Y. Tang, X.-G. Zhang and J.-H. Li, *Chem. Commun.,* 2014, **50**, 12867; (*h*) Z. Meng, S. Sun, H. Yuan, H. Lou and L. Liu, *Angew.*
- <sup>70</sup>*Chem. Int. Ed*., 2014, **53**, 543; (*i*) X. Liu, B. Sun, Z. Xie, X. Qin, L. Liu and H. Lou, *J. Org. Chem*., 2013, **78**, 3104.
- 9 (*a*) C. S. Yeung and V. M. Dong, *Chem. Rev.,* 2011, **111**, 1215; (*b*) C. Liu, H. Zhang, W. Shi and A. Lei, *Chem. Rev.,* 2011, **111**, 1780; (*c*) M. Wasa, B. T. Worrell and J.-Q. Yu, *Angew. Chem., Int. Ed.,* 2010, **49**,
- 75 1275; (*d*) T. Nishikata and B. H. Lipshutz, *Org. Lett.,* 2010, **12**, 1972; (*e*) M. Wan, Z. Meng, H. Lou and L. Liu, *Angew. Chem. Int. Ed*., 2014, **53**, 13845; (*f*) W. Chen, Z. Xie, H. Zheng, H. Lou and L. Liu, *Org. Lett*., 2014, **16**, 5988.
- 10 (*a*) W. Liu, J. Liu, D. Ogawa, Y. Nishihara, X. Guo and Z. Li, *Org.*
- <sup>80</sup>*Lett.,* 2011, **13**, 6272; (*b*) T. Wang, W. Zhou, H. Yin, J.-A. Ma and N. Jiao, *Angew. Chem., Int. Ed.,* 2012, **51**, 10823; (*c*) W.-T. Wei, R.-J. Song and J.-H. Li, *Adv. Synth. Catal.,* 2014, **356**, 1703; (*d*) D. Liu, C. Liu, H. Li and A. Lei, *Chem. Commun.,* 2014, **50**, 3623; (*e*) X.-H, Yang, W.-T. Wei, H.-B. Li, R.-J. Song and J.-H. Li, *Chem. Commun.,*  85 2015. **51**, 4097.
	- 11 G. Deng, K. Ueda, S. Yanagisawa, K. Itami and C.-J. Li, *Chem.Eur. J.,* 2009, **15**, 333.
- 12 (*a*) T. He, L. Yu, L. Zhang, L. Wang and M. Wang, *Org. Lett.,* 2011, **13**, 5016; (*b*) T. He, H. Li, P. Li and L. Wang, *Chem. Commun.,* 2011, <sup>90</sup>**47**, 8946.
- 13 (*a*) R. A. Hughes and C. J. Moody, *Angew. Chem., Int. Ed.,* 2007, **46**, 7930; (*b*) P. Hu, M. Zhang, X. Jie and W. Su, *Angew. Chem., Int. Ed.,*  2012, **51**, 227; (*c*) J. Hassan, M. Sévignon, C. Gozzi, E. Shulz and M. Lemaire, *Chem. Rev.,* 2002, **102**, 1359.
- 95 14 (*a*) L. Chen, E. Shi, Z. Liu, S. Chen, W. Wei, H. Li, K. Xu and X. Wan, *Chem.*-*Eur. J.,* 2011, **17**, 4085; (*b*) Z.-Q. Liu, L. Sun, J.-G. Wang, J. Han, Y.-K. Zhao and B. Zhou, *Org. Lett.,* 2009, **11**, 1437.
- 15 Y. Aoyagi, T. Abe and A. Ohta, *Synthesis*, 1997, 891.
- 16 (*a*) D. Liu, C. Liu, H. Li and A. Lei, *Angew. Chem., Int. Ed*., 2013, **52**, 100 1; (*b*) S. Pan, J. Liu, H. Li, Z. Wang, X. Guo and Z. Li, *Org. Lett.,* 2010, **12**, 1932.
- 17 R. Suresh, R. S. Kumaran, V. Senthilkumar and S. Muthusubramanian, *RSC Adv*., 2014, **4**, 31685.